Baclofen an Anaesthetic Therapeutic: A Commentary

Kimichi Nakamura*

Department of Orthopedic Surgery, Kitahiroshima Town Toyohira Hospital, Hiroshima, Japan

Commentary

Baclofen is a γ-aminobutyric acid agonist that has been licensed for the treatment of spasticity and is widely used in the treatment of neuropathic pain. This medicine has been shown to be effective in the treatment of trigeminal neuralgia in controlled investigations. Baclofen is a gamma-aminobutyric acid agonist that has been approved for the treatment of spasticity and is commonly used in the treatment of neuropathic pain. In controlled studies, this drug has been demonstrated to be effective in the treatment of trigeminal neuralgia. The most effective use of baclofen as an adjuvant analgesic necessitates a thorough understanding of its pharmacology, side effect profile, and dose guidelines, all of which have proven to be valuable in clinical practice [1]. While baclofen was developed as a more brain penetrant form of GABA (γ-aminobutyric acid) for the treatment of epilepsy, its highly effective muscle relaxant qualities led to its approval as a race mate for the treatment of spasticity. Baclofen was approved by the FDA before its receptor, GABAB, was discovered and its full mechanism of action was understood. In recent years, baclofen has been used for a variety of off-label purposes, with the treatment of alcoholism and drug addiction receiving a lot of attention [2]. Baclofen does not pass the blood-brain barrier wall, and its central action is almost non-existent at the indicated therapeutic dose. Massive over dosage, on the other hand, is characterised by central depression, as seen in this patient and previously documented. This medicine is efficiently absorbed after oral administration and is quickly eliminated by the kidneys. It's likely that baclofen interacts with biogenic amines in humans, and animals have shown a drop in cardiac adrenaline and noradrenaline levels. A fast surge in sympathetic activity following a period of depression could cause prolonged tachycardia during the recovery phase when the plasma concentration of baclofen was not at the hazardous level. Depressive disorders are thought to be linked to biogenic amine deficits at neural locations, but it's unclear whether continuous baclofen therapy played a part in the current patient's overdosing when her emotional state appeared to be rather stable in the past [3]. The cough reflex may be overly sensitive, resulting in a chronic, non-productive cough. Standard antitussive treatment is often ineffective in treating this debilitating symptom. Baclofen, a γ-aminobutyric acid (gamma-Aminobutyric acid) agonist, has been found to have antitussive effects in mice via a central mechanism. Baclofen has recently been shown in normal persons to reduce capsaicin-induced cough as well as cough caused by Angiotensin-Converting Enzyme (ACE) inhibitors. We present two patients with chronic, refractory cough who improved symptomatically after a 14-day course of low-dose, oral baclofen, given in a double-blind, placebo-controlled study [4]. In one of the study carried out the effects of systemic injection of the GABA agonist baclofen on food intake in non-fasted rats were examined. In a free-feeding scenario, baclofen (1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg, s.c.) caused a dose-related increase in food intake during the first 90 minutes after treatment, with greatest increases occurring at a dose of 2 mg/kg. Baclofen (0.5 mg/kg and 1.0 mg/kg, s.c.) enhanced food intake in non-fasted rats trained to produce operant responses for food on a fixed-ratio schedule in the 40 min post-drug recording period [5].

References
